| __timestamp | Amphastar Pharmaceuticals, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 12122000 |
| Thursday, January 1, 2015 | 37065000 | 13380000 |
| Friday, January 1, 2016 | 41199000 | 21221000 |
| Sunday, January 1, 2017 | 43415000 | 26887000 |
| Monday, January 1, 2018 | 57564000 | 27863000 |
| Tuesday, January 1, 2019 | 68853000 | 55908000 |
| Wednesday, January 1, 2020 | 67229000 | 59392000 |
| Friday, January 1, 2021 | 60932000 | 69012000 |
| Saturday, January 1, 2022 | 74771000 | 36082000 |
| Sunday, January 1, 2023 | 73741000 | 24537000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Amphastar Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have demonstrated varying levels of investment in R&D. From 2014 to 2023, Amphastar consistently outspent Ligand, with an average R&D expenditure of approximately $55 million annually, compared to Ligand's $35 million. Notably, Amphastar's R&D spending peaked in 2022, reaching nearly $75 million, a 160% increase from 2014. In contrast, Ligand's highest expenditure was in 2021, with $69 million, marking a significant 470% rise from its 2014 figures. This data highlights Amphastar's steady commitment to innovation, while Ligand's spending shows more fluctuation, possibly reflecting strategic shifts or market conditions. As the pharmaceutical landscape continues to change, these investments will likely play a crucial role in shaping future breakthroughs.
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and Ligand Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Comparing Innovation Spending: Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Madrigal Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated Allocate Funds
Comparing Innovation Spending: ADMA Biologics, Inc. and Ligand Pharmaceuticals Incorporated
Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: Perrigo Company plc and Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc.
Research and Development Investment: Ligand Pharmaceuticals Incorporated vs BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.